PMID- 8655293
OWN - NLM
STAT- MEDLINE
DCOM- 19960801
LR  - 20190920
IS  - 0162-3109 (Print)
IS  - 0162-3109 (Linking)
VI  - 31
IP  - 1
DP  - 1995 Nov
TI  - Pentoxifylline therapy in HIV seropositive subjects with elevated TNF.
PG  - 85-91
AB  - Tumor necrosis factor-alpha (TNF-alpha) is thought to induce cachexia in subjects 
      infected with human immunodeficiency virus (HIV), and it has been suggested that 
      HIV-seropositive patients would benefit from treatment with pentoxifylline, a 
      known suppressor of TNF-alpha production. The purpose of the present study was to 
      examine how pentoxifylline at a dose of 800 mg thrice daily would influence the 
      cellular immune system in HIV-seropositive persons with elevated TNF-alpha. Six 
      HIV-seropositive subjects with elevated amounts of TNF-alpha in plasma at least 
      at two occasions were included in an open, controlled, randomized, cross-over 
      study consisting of a 6 week treatment period and a 6 week control period. Blood 
      samples were collected before and at the end of each period. Pentoxifylline 
      treatment did not influence the concentration of plasma-TNF-alpha, subpopulations 
      of blood mononuclear cells, the proliferative responses nor the natural killer 
      (NK), and lymphokine activated killer (LAK) cell activities. Furthermore, 
      pentoxifylline treatment did not influence the weight, temperature, well being, 
      or tiredness of the subjects. However, the patients frequently reported 
      gastrointestinal side effects. In vitro, however, pentoxifylline at 
      suprapharmacological concentrations inhibited the blood mononuclear cell (BMNC) 
      proliferative responses, NK, and LAK cell activities.
FAU - Kruse, A
AU  - Kruse A
AD  - Department of Infectious Diseases, Copenhagen N, Denmark.
FAU - Rieneck, K
AU  - Rieneck K
FAU - Kappel, M
AU  - Kappel M
FAU - Orholm, M
AU  - Orholm M
FAU - Bruunsgaard, H
AU  - Bruunsgaard H
FAU - Ullum, H
AU  - Ullum H
FAU - Skinhoj, P
AU  - Skinhoj P
FAU - Pedersen, B K
AU  - Pedersen BK
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Immunopharmacology
JT  - Immunopharmacology
JID - 7902474
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cachexia/*drug therapy
MH  - Cross-Over Studies
MH  - Female
MH  - Flow Cytometry
MH  - HIV Seropositivity/*drug therapy/*immunology
MH  - Humans
MH  - Immunity, Cellular/*drug effects
MH  - Killer Cells, Lymphokine-Activated/drug effects
MH  - Killer Cells, Natural/drug effects
MH  - Male
MH  - Middle Aged
MH  - Monocytes/drug effects
MH  - Pentoxifylline/administration & dosage/adverse effects/*pharmacology/therapeutic 
      use
MH  - Tumor Necrosis Factor-alpha/*biosynthesis
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 016231099500035X [pii]
AID - 10.1016/0162-3109(95)00035-x [doi]
PST - ppublish
SO  - Immunopharmacology. 1995 Nov;31(1):85-91. doi: 10.1016/0162-3109(95)00035-x.